CELYAD ONCOLOGY (CYAD.BR) Stock Price & Overview
EBR:CYAD • BE0974260896
The current stock price of CYAD.BR is 0.32 EUR. Today CYAD.BR is down by -5.33%. In the past month the price increased by 60%. In the past year, price decreased by -43.86%.
CYAD.BR Key Statistics
- Market Cap
- 7.23M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.16
- Dividend Yield
- N/A
CYAD.BR Stock Performance
CYAD.BR Stock Chart
CYAD.BR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CYAD.BR. When comparing the yearly performance of all stocks, CYAD.BR is one of the better performing stocks in the market, outperforming 76.43% of all stocks.
CYAD.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CYAD.BR. CYAD.BR may be in some trouble as it scores bad on both profitability and health.
CYAD.BR Earnings
CYAD.BR Forecast & Estimates
CYAD.BR Groups
Sector & Classification
CYAD.BR Financial Highlights
Over the last trailing twelve months CYAD.BR reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 33.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYAD.BR Ownership
CYAD.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.75 | 39.556B | ||
| 1AE | ARGENX SE | 26.63 | 39.494B | ||
| 22UA | BIONTECH SE-ADR | N/A | 16.555B | ||
| ABVX | ABIVAX SA | N/A | 7.852B | ||
| 2X1 | ABIVAX SA | N/A | 7.844B | ||
| GXE | GALAPAGOS NV | N/A | 1.899B | ||
| GLPG | GALAPAGOS NV | N/A | 1.898B | ||
| NANO | NANOBIOTIX | N/A | 1.59B | ||
| IVA | INVENTIVA SA | N/A | 1.172B | ||
| 6IV | INVENTIVA SA | N/A | 1.114B | ||
| PHIL | PHILOGEN SPA | 18.01 | 669.596M | ||
| GNFT | GENFIT | 899.51 | 468.027M | ||
| VLA | VALNEVA SE | N/A | 427.122M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About CYAD.BR
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Company Info
IPO: 2013-07-05
CELYAD ONCOLOGY
Rue Andre Dumont 9
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 18
Phone: 3210394100
CELYAD ONCOLOGY / CYAD.BR FAQ
What does CELYAD ONCOLOGY do?
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
What is the current price of CYAD stock?
The current stock price of CYAD.BR is 0.32 EUR. The price decreased by -5.33% in the last trading session.
Does CYAD stock pay dividends?
CYAD.BR does not pay a dividend.
How is the ChartMill rating for CELYAD ONCOLOGY?
CYAD.BR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of CELYAD ONCOLOGY (CYAD.BR)?
CELYAD ONCOLOGY (CYAD.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
Who owns CELYAD ONCOLOGY?
You can find the ownership structure of CELYAD ONCOLOGY (CYAD.BR) on the Ownership tab.